Literature DB >> 17357254

Nonreceptor tyrosine kinases in prostate cancer.

Yu-Ming Chang1, Hsing-Jien Kung, Christopher P Evans.   

Abstract

BACKGROUND: Carcinoma of the prostate (CaP) is the most commonly diagnosed cancer in men in the United States. Signal transduction molecules such as tyrosine kinases play important roles in CaP. Src, a nonreceptor tyrosine kinase (NRTK) and the first proto-oncogene discovered is shown to participate in processes such as cell proliferation and migration in CaP. Underscoring NRTK's and, specifically, Src's importance in cancer is the recent approval by the US Food and Drug Administration of dasatinib, the first commercial Src inhibitor for clinical use in chronic myelogenous leukemia (CML). In this review we will focus on NRTKs and their roles in the biology of CaP.
MATERIALS AND METHODS: Publicly available literature from PubMed regarding the topic of members of NRTKs in CaP was searched and reviewed.
RESULTS: Src, FAK, JaK1/2, and ETK are involved in processes indispensable to the biology of CaP: cell growth, migration, invasion, angiogenesis, and apoptosis.
CONCLUSIONS: Src emerges as a common signaling and regulatory molecule in multiple biological processes in CaP. Src's relative importance in particular stages of CaP, however, required further definition. Continued investigation of NRTKs will increase our understanding of their biological function and potential role as new therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17357254      PMCID: PMC1813931          DOI: 10.1593/neo.06694

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  127 in total

Review 1.  Mechanisms of focal adhesion kinase regulation.

Authors:  Lee Ann Cohen; Jun-Lin Guan
Journal:  Curr Cancer Drug Targets       Date:  2005-12       Impact factor: 3.428

Review 2.  Treatment for advanced tumors: SRC reclaims center stage.

Authors:  Justin M Summy; Gary E Gallick
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

3.  Links between Fer tyrosine kinase expression levels and prostate cell proliferation.

Authors:  P Allard; A Zoubeidi; L T Nguyen; S Tessier; S Tanguay; M Chevrette; A Aprikian; S Chevalier
Journal:  Mol Cell Endocrinol       Date:  2000-01-25       Impact factor: 4.102

4.  The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.

Authors:  Y Xie; K Xu; B Dai; Z Guo; T Jiang; H Chen; Y Qiu
Journal:  Oncogene       Date:  2006-01-05       Impact factor: 9.867

5.  Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.

Authors:  Antimo Migliaccio; Marina Di Domenico; Gabriella Castoria; Merlin Nanayakkara; Maria Lombardi; Antonietta de Falco; Antonio Bilancio; Lilian Varricchio; Alessandra Ciociola; Ferdinando Auricchio
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

6.  PSK, a novel STE20-like kinase derived from prostatic carcinoma that activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and regulates actin cytoskeletal organization.

Authors:  T M Moore; R Garg; C Johnson; M J Coptcoat; A J Ridley; J D Morris
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

7.  Bombesin modulates the association of Src with a nuclear 110-kd protein expressed in dividing prostate cells.

Authors:  P Allard; P Beaulieu; A Aprikian; S Chevalier
Journal:  J Androl       Date:  2000 May-Jun

8.  The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer.

Authors:  Jian Zhoul; Gina Hernandez; Szu-Wei Tu; Chien-Ling Huang; Ching-Ping Tseng; Jer-Tsong Hsieh
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

9.  Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein.

Authors:  Anupama Kotha; Madhavi Sekharam; Lucia Cilenti; Khandaker Siddiquee; Annette Khaled; Antonis S Zervos; Bradford Carter; James Turkson; Richard Jove
Journal:  Mol Cancer Ther       Date:  2006-03       Impact factor: 6.261

10.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

View more
  62 in total

1.  PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.

Authors:  Laurent Lessard; David P Labbé; Geneviève Deblois; Louis R Bégin; Serge Hardy; Anne-Marie Mes-Masson; Fred Saad; Lloyd C Trotman; Vincent Giguère; Michel L Tremblay
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

2.  Reorganization of the integrin alpha2 subunit controls cell adhesion and cancer cell invasion in prostate cancer.

Authors:  Severine Van Slambrouck; Aaron R Jenkins; Anntherese E Romero; Wim F A Steelant
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

3.  Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.

Authors:  Annabelle Chow; Amy Wong; Giulio Francia; Shan Man; Robert S Kerbel; Urban Emmenegger
Journal:  Invest New Drugs       Date:  2013-06-02       Impact factor: 3.850

4.  Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo.

Authors:  Takashi Kobayashi; Takahiro Inoue; Yosuke Shimizu; Naoki Terada; Atsushi Maeno; Yoichiro Kajita; Toshinari Yamasaki; Tomomi Kamba; Yoshinobu Toda; Yoshiki Mikami; Tomomi Yamada; Toshiyuki Kamoto; Osamu Ogawa; Eijiro Nakamura
Journal:  Mol Endocrinol       Date:  2010-03-04

5.  Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer.

Authors:  Sharanjot Saini; Shahana Majid; Varahram Shahryari; Z Laura Tabatabai; Sumit Arora; Soichiro Yamamura; Yuichiro Tanaka; Rajvir Dahiya; Guoren Deng
Journal:  Mol Cancer Ther       Date:  2014-05-09       Impact factor: 6.261

6.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

7.  FYN is overexpressed in human prostate cancer.

Authors:  Edwin M Posadas; Hikmat Al-Ahmadie; Victoria L Robinson; Ramasamy Jagadeeswaran; Kristen Otto; Kristen E Kasza; Maria Tretiakov; Javed Siddiqui; Kenneth J Pienta; Walter M Stadler; Carrie Rinker-Schaeffer; Ravi Salgia
Journal:  BJU Int       Date:  2008-10-16       Impact factor: 5.588

8.  Effects of TRPM8 on the proliferation and angiogenesis of prostate cancer PC-3 cells in vivo.

Authors:  Guangbin Zhu; Xinghuan Wang; Zhonghua Yang; Hong Cao; Zhe Meng; Yongzhi Wang; Dong Chen
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

9.  Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.

Authors:  Y-M Chang; L Bai; S Liu; J C Yang; H-J Kung; C P Evans
Journal:  Oncogene       Date:  2008-08-04       Impact factor: 9.867

10.  Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Authors:  J Rafael Sierra; Virna Cepero; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-04-12       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.